Company Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs.
Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for people with relapsed and refractory acute myeloid leukemia for bone marrow transplant; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.
The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA.
It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPα immunotherapy targeted radiotherapy; and Immedica pharma for licensed the rights to commercialize Iomab-B.
The company is based in New York, New York.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Sandesh Seth |
Contact Details
Address: 100 Park Avenue, 23rd Floor New York, New York 10017 United States | |
| Phone | 646 677 3870 |
| Website | actiniumpharma.com |
Stock Details
| Ticker Symbol | ATNM |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001388320 |
| CUSIP Number | 00507W107 |
| ISIN Number | US00507W2061 |
| Employer ID | 88-0378336 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sandesh C. Seth M.B.A., M.S. | Chairman and Chief Executive Officer |
| Steven O'Loughlin BS | Chief Financial Officer and Corporate Secretary |
| Dr. Paul Diamond Esq., Ph.D. | Vice President of Patent and Legal Counsel |
| Dr. Avinash Desai M.D. | Chief Medical Officer |
| Jenny Hsieh | Chief Strategy Officer |
| Sunitha Lakshminarayanan | Senior Vice President, Head of CMC and Product Development |
| Caroline Yarbrough | Chief Commercial Officer |
| Lynn M. Bodarky M.B.A. | Chief Business Officer |
| J. C. Simeon | Executive Director of Quality Assurance |
| Dr. Madhuri Vusirikala M.D. | Vice President of Clinical Development BMT and Cellular Therapy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 5, 2024 | 10-Q | Quarterly Report |
| Aug 5, 2024 | 8-K | Current Report |
| Apr 26, 2024 | 10-Q | Quarterly Report |
| Mar 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 29, 2024 | 10-K | Annual Report |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 5, 2024 | EFFECT | Notice of Effectiveness |
| Feb 2, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Jan 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Dec 1, 2023 | 8-K | Current Report |